[3b b,7,7,17a a- -5-ene-17b b,19-diol (6) and [3,3,7,7,-2 
Aromatase is a cytochrome P-450 enzyme which catalyzes the conversion of androst-4-ene-3,17-dione (androstenedione) to estrone through three sequential oxygenations of the 19-methyl group. 1) Inhibitors of aromatase have recently attracted interest not only in the treatment of advanced estrogen-dependent breast cancer 2) but also in the elucidation of the spatial aspects of the active-site of the enzyme as well as the still unsolved mechanism of the aromatase reaction. 3) We have previously reported that the androst-4-en-17-one (2), 4) 3-deoxy analog of the natural substrate androstenedione, and its 5-ene isomer 1 5) (Chart 1) are very potent competitive inhibitors of aromatase, although they have no carbonyl group at C-3 which is thought to be essential for tight binding of the substrate to the active site of aromatase. We have recently reported that some competitive inhibitors of aromatase, 6-alkyl 6) and 6-oxo 7) androstenediones, can serve as substrates for the enzyme to afford estrogens when they are incubated with human placental microsomes. Thus, it was of interest to investigate the relationship between the aromatase inhibitory activity of the 3-deoxy compounds, 1 and 2, and their ability to act as substrates. It was postulated that the aromatase products of compounds 1 and 2, obtained by incubation with placental microsomes, would be a mixture of the 19-hydroxy and 19-oxo derivatives 1) as well as their 17b-alcohol analogs produced by the action of 17b-hydroxysteroid dehydrogenase 8) in each incubation system. The aromatase-catalyzed 19-oxygenation activity could be determined by GC-MS analysis of the 17b,19-dihydroxy steroids obtained after NaBH 4 reduction of the mixture of 19-oxygenated products.
8b) Thus, we synthesized the deuterium labeled 17b,19-diols 6 and 15-d 4 as internal standards.
Results and Discussion
We initially focused on the preparation of [3b,7,7,17a-2 H 4 ] androst-5-ene-17b,19-diol (6) . [7,7- 2 H 2 ]3b-Acetoxyandrost-5-en-17-one 9) (d 2 , 98.6 atom%) was converted [7,7-2 H 2 ]3b -p-toluenesulfonyloxy-19-(tert-butyldimethyl-siloxy)androst-5-en-17-one (3) according to a previously reported method 5) involving the addition of hypobromous acid to a double-bond at C-5, followed by the "hypoiodate reaction" (lead tetraacetate, iodine, and hn) and subsequent zinc dust reduction (Fig. 1) . 10) Reductive elimination of the 3b-tosylate, 3, with zinc dust-D 2 O in the presence of NaI 11) produced the 3b-deuterio compound 4 (d 3 , 89.5 atom%) ( Table  1) . Deprotection of the 19-tert-butyldimethylsilyl (TBDMS) group of compound 4 with acid followed by reduction of the 17-oxo function with NaBD 4 afforded the deuterated 17b,19-diol 6 (d 4 , 79.8 atom%).
We then synthesized another deuterium-labeled steroid, [3,3,7,7-2 H 4 ]androst-4-ene-17b,19-diol (15-d 4 ). Non-labeled compound 15 has been synthesized previously using desulfurization of the 3,3-ethylenedithio derivative of 19-(tert-butyldimethylsiloxy)androst-4-ene-3,17-dione with a sodium-liquid ammonia-MeOH system. 4) This synthesis was unsuitable for introduction of deuterium atoms at C-3 because deuterated liquid ammonia is not readily available. We therefor employed another route to synthesize the deuterated compound 15. 3b-Acetoxy-19-(tert-butyldimethylsiloxy)androst-5-en17b-ol (7), obtained by NaBH 4 reduction of the known 17-oxo derivative, 12) was converted to 3b,17b-diacetate, 8. Treatment of this with tert-butylhydroperoxide and pyridinium dichromate in the presence of Celite 545 13) gave the 7-oxo compound, 9, in 63% yield from compound 7 (Fig.  2) . After hydrolysis of acetate 9 with K 2 CO 3 , the reductive deoxygenation with AlCl 2 H 2 or AlCl 2 D 2 (generated from LiAlH 4 and AlCl 3 or LiAlD 4 and AlCl 3 in ether, respectively) yielded the 5-ene compound, 11, or its 7,7-deuterio analog (11-d 2 , d 2 Ͼ99 atom%) in good yield. This 3b,17b-diol, 11 or 11-d 2 , was oxidized with Jones reagent to the 3,17-dione, 12 or 12-d 2 , followed by treatment with 0.48 mol eq of NaBH 4 to give the 17b-ol, 13, or its 7,7-deuterio analog, 13-d 2 The deuterium content of compounds 6 and 15-d 4 was very high making them suitable internal standards for GC-MS analysis.
The mass spectra and deuterium content of the trimethylsilyl derivatives of the deuterated steroids 6 and 15-d 4 are shown in Fig. 3 and Table 1 . In every case, no molecular ion (M ϩ , m/z 434) was observed and the base ion peak (m/z 344) was a fragment ion corresponding to M ϩ Ϫ90, with a deuterium content different from that of the M ϩ ion obtained by the direct MS method. During fragmentation of the trimethylsilyl (TMS)-derivative, a deuterium incorporated at C-3 of the 4-ene steroid, 15-d 4 , or C-7 of the 5-ene steroid, 6, would be lost. However, the deuterium content (d 3 , 61.0 and 64.8 atom% for 6 and 15-d 4 , respectively) is still sufficient for use as an internal standard for GC-MS analysis.
Using a selected-ion monitoring method with the fragment ion M ϩ Ϫ90 (m/z 344 and 348 for non-labeled steroid and internal standard, respectively), compounds 6 and 15, potential metabolites of inhibitors 1 and 2 of aromatase, could be detected in amounts as low as 50-80 pg (s/nϭ10).
Experimental
Melting points were measured on a Yanagimoto melting point apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer Fourier transform (FT)-IR 1725 spectrophotometer and UV spectra in 95% EtOH solution on a Hitachi 150-20 spectrophotometer.
1 H-NMR spectra were obtained in CDCl 3 solution with a JEOL EX 270 (270 MHz) spectrometer using tetramethylsilane as an internal standard, and direct MS with a JEOL JMS-DX 303 spectrometer. GC-MS was carried out with a Finnigan MAT SSQ 710 GC-MS instrument or HP 5970B GC-MS system. TLC was performed on E. Merk pre-coated silica-gel plates. Column chromatography was conducted with silica-gel (E. Merk, 70-230 mesh). Bis(trimethylsilyl)-trifluoroacetamide (BSTFA) was obtained from Tokyo Kasei Kogyo Co.
[7,7-2 H 2 ]3b b-Hydroxyandrost-5-en-17-one This was obtained from 3b-(tert-butyldimethylsiloxy)androst-5-en-7-one according to the published method 9) in which deoxygenation of the C-7 carbonyl function was carried out using LiAlD 4 39 mmol), in ethyleneglycol dimethyl ether (24 ml), deuterium oxide (2.9 ml), NaI (1.12 g, 7.46 mmol) and zinc dust (1.07 g, 16.4 mmol) were added and the suspension was refluxed under Ar with stirring for 8 h. The reaction mixture was filtered and the residue was washed with AcOEt (50 ml). The combined filtrate was diluted with AcOEt (150 ml), washed with 5% NaHCO 3 solution and brine, and dried (Na 2 SO 4 ). After evaporation of the solvent, the residue was purified by column chromatography. Elution with hexane-AcOEt (7 : 1) gave a crude product which was recrystallized from acetone to give compound 4 as colorless needles (410 mg, 75%), mp 80-83°C (lit. 5) mp 85-87°C for non-labeled form). 74 mmol) in THF (5.3 ml)-2-propanol (8.3 ml), 3 mol/l HCl (5.3 ml) was added and the mixture was stirred at room temperature for 2 d. After this time, the reaction mixture was diluted with AcOEt (100 ml), washed with 5% NaHCO 3 and brine, and dried (Na 2 SO 4 ). After evaporation of the solvent, the residue was purified by column chromatography. Elution with hexane-AcOEt (3 : 1) gave a crude product which was recrystallized from acetone to give compound 5 (94 mg, 75%), mp 120-121°C (lit.
5) mp 120-124°C for non-labeled form To a solution of 17-ketone 5 (20 mg, 0.068 mmol) in MeOD (3 ml), NaBD 4 (6 mg, 0.14 mmol) was added at 0°C and the mixture was stirred at 0°C for 30 min. After this time, the reaction mixture was diluted with AcOEt (30 ml), washed with 5% HCl, 5% NaHCO 3 , and brine, sequentially, and dried (Na 2 SO 4 ). After evaporation of the solvent, the residue was recrystallized from AcOEt-Et 2 O to give compound 6 as colorless prisms (15 mg . 3b b-Acetoxy-19-(tert-butyldimethylsiloxy)androst-5-en-17b b-ol (7) To a solution of 3b-acetoxy-19-(tert-butyldimethylsiloxy)androst-5-en-17-one 12) (244 mg, 0.53 mmol) in EtOH (12 ml), NaBH 4 (10 mg, 0.26 mmol) was added under ice-cooling. The reaction mixture was stirred at 0°C for 4 h. After extraction with AcOEt (60 mlϫ2), the organic layer was washed with 5% HCl, 5% NaHCO 3 and brine, sequentially, and dried (Na 2 SO 4 ). After evaporation of the solvent, the oily product obtained was purified by column chromatography. Elution with hexane-AcOEt (3 : 1) gave compound 7 as colorless prisms (199 mg, 81%), mp 123-124°C (acetone 19-(tert-Butyldimethylsiloxy)androst-5-en-3b b,17b b-diyl Diacetate (8) A solution of compound 7 (200 mg, 0.30 mmol) in pyridine (2 ml) and Ac 2 O (1 ml) was allowed to stand at room temperature for 12 h. After this time, the reaction mixture was poured into ice-water (20 ml), and then extracted with AcOEt (50 ml). The organic layer was washed with 5% HCl, 5% NaHCO 3 , and brine, sequentially, and dried (Na 2 SO 4 ). After evaporation of the solvent, the crystalline solid obtained was recrystallized from hexane to give compound 8 as colorless needles (191 mg, 88%), mp 121-123°C. 3b b,17b b-Diacetoxy-19-(tert-butyldimethylsiloxy)androst-5-en-7-one (9) tert-BuOOH (0.26 ml) was added dropwise to a mixture of compound 8 (252 mg, 0.50 mmol), benzene (7.7 ml), Celite 545 (774 mg), and pyridinium dichromate (952 mg, 0.40 mmol) under ice-cooling and the resulting mixture was stirred at room temperature for 3 d, diluted with AcOEt (50 ml), and filtered through a pad of Celite 545 which was washed with AcOEt (50 ml). The combined filtrate was washed with 5% HCl, 5% NaHCO 3 and brine, sequentially, and dried (Na 2 SO 4 ). The solvent was evaporated to dryness to give an oily product, which was purified by column chromatography. Elution with hexane-AcOEt (5 : 1) gave unchanged starting material (53 mg, 21%) as a less polar steroid and compound 9 (163 mg, 63%) as a more polar steroid, mp 118-120°C (hexane) as colorless needles. 1 3b b,17b b-Dihydroxy-19-(tert-butyldimethylsiloxy)androst-5-en-7-one (10) To a solution of compound 9 (170 mg, 0.33 mmol) in MeOH (6 ml) and water (1 ml), K 2 CO 3 (90 mg, 0.65 mmol) was added and the mixture was heated at 60°C for 3 h. After this time, the reaction mixture was concentrated to about 2 ml and extracted with AcOEt (50 ml). The organic layer was washed with brine, and dried (Na 2 SO 4 ). After evaporation of the solvent, the crystalline solid obtained was recrystallized from acetone to give compound 10 (140 mg, 98%) as colorless prisms, mp 185-186.5°C. 1 0.60 mmol) in dry Et 2 O (4 ml) was added dropwise at 0°C to this suspension. The mixture was heated under reflux for 30 min under N 2 , and then cooled to room temperature. A solution of compound 10 (100 mg, 0.23 mmol) in dry THF (2 ml) was added to the mixture, and then heated under reflux for 2.5 h and cooled. Water was carefully added to the reaction mixture, followed by extraction with AcOEt (100 ml). The organic layer was washed with 5% HCl, 5% NaHCO 3 and brine, sequentially, and dried (Na 2 SO 4 ). Evaporation of the solvent afforded a solid which was recrystallized from acetone to give compound 11 (77 mg, 79%) as colorless prisms, mp 205-206°C. 1 ]Analog Jones reagent (0.17 ml) was added to a solution of compound 11 (100 mg, 0.24 mmol) in acetone under ice-cooling. The resulting mixture was stirred for 25 min. After this time, the reaction mixture was poured into ice-water (50 ml), extracted with AcOEt (100 mlϫ2), washed with 5% NaHCO 3 and brine, and dried (Na 2 SO 4 ). Evaporation of the solvent afforded an oily product (105 mg) which was dissolved in acetone (2 ml). pToluenesulfonic acid monohydrate (3.7 mg, 0.02 mmol) was added to this solution and then allowed to stand at room temperature for 3 h, diluted with AcOEt (50 ml), and washed with 5% NaHCO 3 and brine, and dried (Na 2 SO 4 ). Evaporation of the solvent gave an oily product which was purified by column chromatography. Elution with hexane-AcOEt (3 : 1) gave compound 12 (21 mg, 21%) as colorless needles, mp 156-157.5°C. 17b b-Hydroxy-19-(tert-butyldimethylsiloxy)androst-4-en-3-one (13) and Its [7,7-2 H 2 ]Analog NaBH 4 (2.1 mg, 0.056 mmol) was added to a solution of compound 12 (49 mg, 0.12 mmol) in MeOH (2 ml) under ice-cooling, and the resulting mixture was stirred for 3 h, diluted with AcOEt (50 ml), washed with 5% HCl, 5% NaHCO 3 and brine, sequentially, and dried (Na 2 SO 4 ). Evaporation of the solvent yielded an oily product which was purified by preparative silica-gel TLC (two developments with hexane-AcOEt (1 : 1)) to give compound 13 as colorless prisms (35 mg, 70%), mp 141-143°C. 
